AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01796795
Drug: SR-T100 gel with 1.0% of SM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Trial: NCT06204003
Drug: Cannabis/Hemp Isolate Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation: CBD (99%; 0.1% THC isolate)
Trial: NCT06076837
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
Trial: NCT05530252
Drug: Oral biological antimicrobial gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Trial: NCT05530252
Drug: minocycline hydrochloride ointment
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Trial: NCT05913232
Drug: H-1337 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT05913232
Drug: H-1337 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT05913232
Drug: H-1337 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT05891379
Drug: oral immunosuppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
Trial: NCT06519578
Drug: hepatic artery infusion chemotherapy
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.
Trial: NCT06152991
Drug: GODEX
RxNorm normalized name: Dodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg
Trial: NCT06152991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg.
Trial: NCT05655299
Drug: VTX958 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A
Trial: NCT05655299
Drug: VTX958 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B
Trial: NCT05655299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04708366
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Trial: NCT04708366
Drug: Macrogol 400
RxNorm normalized name: Macrogol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Trial: NCT04446039
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT06651541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation without the active ingredient
Trial: NCT05760781
Drug: STSG-0002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04762589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
Trial: NCT05659953
Drug: LMT503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one of several different oral doses of LMT503 once daily
Trial: NCT05659953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one of several different oral doses of Placebo once daily
Trial: NCT05718921
Drug: YR001 Dose B on low body surface area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single topical dose
Trial: NCT05718921
Drug: Placebo on low body surface area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single topical dose
Trial: NCT05718921
Drug: YR001 Dose B on high body surface area twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Multiple topical dose
Trial: NCT05718921
Drug: Placebo on high body surface area twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Multiple topical dose
Trial: NCT02039869
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid suppressing medication (over the counter)
Trial: NCT05919186
Drug: EmbryORP®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
Trial: NCT04204967
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl
Trial: NCT05886374
Drug: HMPL-415S1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
Trial: NCT00000996
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04291469
Drug: Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
Trial: NCT05691530
Drug: rDENdelta30/31-7164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
Trial: NCT05999357
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDQ443 tablets, orally administered
Trial: NCT06284265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT05169229
Drug: Vancomycin + Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
Trial: NCT05930210
Drug: ENERGI-F703 GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
Trial: NCT05930210
Drug: ENERGI-F703 matched vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Trial: NCT06065670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched sugar tablet
Trial: NCT03708900
Drug: LCI699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
Trial: NCT06654921
Drug: Standard medication therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication therapy will be performed according to the national and international guidelines.
Trial: NCT04809142
Drug: TQB2450 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Trial: NCT04809142
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
Trial: NCT05119751
Drug: tree 12 SQ-Bet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAILY DOSE OF AIT TABLET
Trial: NCT05119751
Drug: GRASS 2800 BAU
RxNorm normalized name: Timothy grass pollen extract 2800 BAU [Grastek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAILY DOSE OF AIT TABLET
Trial: NCT05119751
Drug: HDM 12 SQ-HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAILY DOSE OF AIT TABLET
Trial: NCT05902260
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
Trial: NCT06601803
Drug: sterile saline solution
RxNorm normalized name: Blairex Sterile Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
Trial: NCT06601803
Drug: Surgiphor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant
Trial: NCT06587880
Drug: Bone Bioactive Liquid
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
Trial: NCT06587880
Drug: Warm Saline Mouth Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
Trial: NCT06592612
Drug: Second-line systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
Trial: NCT05324774
Drug: 9MW0813
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously.
Trial: NCT06590844
Drug: Injectable coenzyme I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
Trial: NCT05269160
Drug: Dermaprazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
Trial: NCT05269160
Drug: Dermaprazole 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
Trial: NCT06600880
Drug: MK-6240
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
Trial: NCT06598969
Drug: Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
Trial: NCT05538507
Drug: smart soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe AD, mild or moderate AD and MCI will be given smart soup
Trial: NCT05538507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with MCI will be given placebo
Trial: NCT06590545
Drug: KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
Trial: NCT05063994
Drug: Chronocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-encapsulated hydrocortisone modified-release capsule for oral administration.
Trial: NCT05715931
Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle.
Trial: NCT04730804
Drug: ALXN1830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1830 will be administered as SC infusion(s).
Trial: NCT04730804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as SC infusion(s).
Trial: NCT04856358
Drug: GLPG3121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3121 modified-release tablet
Trial: NCT04856358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03831152
Drug: ADV7103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single group assignment
Trial: NCT05327348
Drug: Normal Saline 10 mL Injection
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
Trial: NCT05261646
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo（Stage 1；Stage 2）
Trial: NCT06326814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Trial: NCT05544019
Drug: SGR-1505
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGR-1505 will be administered orally.
Trial: NCT06639711
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Trial: NCT06287580
Drug: chlorthalidone 25 mg
RxNorm normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone, 25 mg orally once daily
Trial: NCT06059664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
Trial: NCT06653972
Drug: Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
Trial: NCT06591910
Drug: Chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Serplulimab combined with chemotherapy
Trial: NCT06594692
Drug: CAPOX Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
Trial: NCT06590090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
Trial: NCT04592822
Drug: WD-1602
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dabigatran etexilate mesylate granules for oral suspension
Trial: NCT04592822
Drug: Pradaxa®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dabigatran etexilate capsules
Trial: NCT00786058
Drug: OFF in experimental arm
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
Trial: NCT00000721
Drug: CD4 Antigens
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06654882
Drug: TNFi (Tumor Necrosis Factor inhibitor) medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly
Trial: NCT06586866
Drug: JK-1201I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
Trial: NCT06588036
Drug: Smecta
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4 will be given smecta scahet
Trial: NCT06723002
Drug: Atherolive 500mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Trial: NCT06723002
Drug: Atherolive 1000/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Trial: NCT06723002
Drug: Placbo_Atherolive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Trial: NCT06592326
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9MW2821, 1.25mg/kg, intravenous (IV) infusion
Trial: NCT05502809
Drug: Deep-frozen platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryopreserved platelets
Trial: NCT05767749
Drug: lidocaine + epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
Trial: NCT06599918
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.